RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

NCT01009346 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Toxicity

Conditions

Head and Neck Cancer

Interventions

DRUG: RAD001
DRUG: Cetuximab
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]